The evolving role of gemcitabine in the management of breast cancer Journal Article


Author: Seidman, A. D.
Article Title: The evolving role of gemcitabine in the management of breast cancer
Abstract: Despite the common clinical use of numerous active cytotoxic agents for breast cancer therapy, and the combinations that are derived from them, the median survival for patients with metastatic breast cancer has not been dramatically improved over the past two decades. Furthermore, when the expected outcome of treatment is not cure, optimizing the dynamic equilibrium between chemotherapy-induced side effects and the benefits attributable to chemotherapy-mediated relief of cancer-related symptomatology becomes paramount. The search for active agents to this end has recently included the clinical evaluation of the novel nucleoside analogue gemcitabine (2′,2′-difluorodeoxycytidine). This review summarizes the recent and current development of this agent. Copyright © 2001 S. Karger AG, Basel.
Keywords: cancer survival; controlled study; treatment outcome; clinical trial; review; cisplatin; cytotoxic agent; doxorubicin; fluorouracil; cancer combination chemotherapy; monotherapy; capecitabine; gemcitabine; paclitaxel; chemotherapy; cytarabine; methotrexate; metastasis; controlled clinical trial; breast cancer; antimetabolites, antineoplastic; nausea; neuropathy; vomiting; antineoplastic combined chemotherapy protocols; cyclophosphamide; antineoplastic activity; breast neoplasms; cancer therapy; tamoxifen; epirubicin; taxane derivative; trastuzumab; navelbine; deoxycytidine; hematologic disease; pamidronic acid; tamoxifen citrate; nucleoside derivative; humans; human; female; priority journal; phase ii studies; 2′,2′-difluorodeoxycytidine
Journal Title: Oncology
Volume: 60
Issue: 3
ISSN: 0030-2414
Publisher: S. Karger AG  
Date Published: 2001-04-01
Start Page: 189
End Page: 198
Language: English
DOI: 10.1159/000055318
PUBMED: 11340369
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 21 May 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Andrew D Seidman
    318 Seidman